Acquisitions of Assets - Additional Information (Details)	1 Months Ended					3 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2023 USD ($) shares	Nov. 30, 2023 USD ($)	Feb. 28, 2022 USD ($)	Sep. 30, 2021 USD ($) Agreements shares	Jun. 30, 2020 USD ($)	Dec. 31, 2023 USD ($)	Sep. 30, 2024 USD ($) Milestones	Dec. 31, 2023 USD ($)
Amgen Inc.
Business Acquisition [Line Items]
Number of license agreements | Agreements				2
Vanderbilt IPR&D Assets
Business Acquisition [Line Items]
Contingent consideration deemed due or payable							$ 0
BlackThorn Merger Agreement
Business Acquisition [Line Items]
Contingent consideration, milestone payment settled in cash					$ 10,000,000
Number of milestone achieved | Milestones							0
BlackThorn Merger Agreement | BlackThorn Therapeutics, Inc.
Business Acquisition [Line Items]
Contingent consideration deemed due or payable							$ 0
Contingent consideration payable in cash	$ 2,300,000
Acquired in-process research and developed expense						$ 60,800,000
BlackThorn Merger Agreement | BlackThorn Therapeutics, Inc. | Common Stock
Business Acquisition [Line Items]
Shares issued based on volume weighted average price per share prior to date milestone was met | shares	6,072,445
BlackThorn Merger Agreement | navacaprant
Business Acquisition [Line Items]
Milestone payment due description							milestone payment that became due in October 2023 upon dosing the first patient in the Phase 3 clinical trial for navacaprant,
BlackThorn Merger Agreement | navacaprant | Maximum | Development and Regulatory Approval Milestones
Business Acquisition [Line Items]
Contingent consideration					365,000,000
BlackThorn Merger Agreement | navacaprant | Maximum | Sales-based Milestones
Business Acquisition [Line Items]
Contingent consideration					450,000,000
BlackThorn Merger Agreement | NMRA-511 | Maximum | Development and Regulatory Approval Milestones
Business Acquisition [Line Items]
Contingent consideration					100,000,000
BlackThorn Merger Agreement | NMRA-511 | Maximum | Sales-based Milestones
Business Acquisition [Line Items]
Contingent consideration					$ 100,000,000
BlackThorn Carveout Plan
Business Acquisition [Line Items]
Number of milestone achieved | Milestones							0
Contingent consideration deemed due or payable							$ 0
Asset acquisition compensation recognized and paid								$ 1,800,000
Amgen Inc. Licenses | Amgen Inc.
Business Acquisition [Line Items]
Number of milestone achieved | Milestones							0
Contingent consideration deemed due or payable							$ 0
Amgen Inc. Licenses | Amgen Inc. | Series A-2
Business Acquisition [Line Items]
Upfront consideration transferred shares | shares				20,000,000
Acquisition date fair value of shares transferred				$ 157,000,000
Amgen Inc. Licenses | Amgen Inc. | Maximum | Case One
Business Acquisition [Line Items]
Contingent consideration payable in cash				360,000,000
Amgen Inc. Licenses | Amgen Inc. | Maximum | Commercial Milestone Payment | Case Two
Business Acquisition [Line Items]
Contingent consideration payable in cash				$ 360,000,000
Vanderbilt License
Business Acquisition [Line Items]
Contingent consideration, milestone payment settled in cash		$ 2,000,000
Number of milestone achieved | Milestones							0
Acquired in-process research and development						$ 800,000
Vanderbilt License | Maximum | Achievement of Specified Development Events
Business Acquisition [Line Items]
Contingent consideration payable in cash			$ 42,400,000
Vanderbilt License | Maximum | Achievement of Specified Commercialization Events
Business Acquisition [Line Items]
Contingent consideration payable in cash			380,000,000
Vanderbilt License | Vanderbilt IPR&D Assets
Business Acquisition [Line Items]
Upfront cash payment			$ 13,000,000